Image-guided stereotactic body radiation therapy for localized prostate cancer

Jin Kyu Kang, Chul Koo Cho, Chul Won Choi, Seong Yul Yoo, Mi Sook Kim, Kwang Mo Yang, Hyung Jun Yoo, Jin Ho Kim, Young Seok Seo, Dong Han Lee, Moon Ki Jo

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Purpose.We report the results of a retrospective study of stereotactic body radiation therapy (SBRT) using CyberKnife for localized prostate cancer. The study focused on the safety and feasibility of this treatment modality. Materials and methods. Between October 2002 and December 2007, 44 patients suffering from localized adenocarcinoma of the prostate were treated with SBRT using CyberKnife at the Korea Cancer Center Hospital. The patients were divided into 3 groups: a low-risk group (5 patients), an intermediate-risk group (10 patients), and a high-risk group (29 patients). Five patients received 32 Gy in 4 fractions, 28 patients received 34 Gy in 4 fractions, and 11 patients received 36 Gy in 4 fractions. Results. The median age of the patients was 69 years (range, 53-79 years) and the median duration of follow-up 40 months (range, 12-78 months). There were 6 acute and 3 late grade 2 urinary toxicities, and 4 acute and 5 late grade 2 rectal toxicities, but there were no grade 3 or higher treatment-related toxicities. The 5-year cause-specific survival rate and progression-free survival rate were both 100%. At last follow-up, the biochemical failure-free rate of the low-risk, intermediate-risk and high-risk patients was 100%, 100% and 90.8%, respectively. Conclusion. SBRT using CyberKnife for localized prostate cancer is safe and well tolerated. We obtained promising results with 34 Gy in a 4-fraction regimen especially for the high-risk patients. Free full text available at www.tumorionline.it.

Original languageEnglish
Pages (from-to)43-48
Number of pages6
JournalTumori
Volume97
Issue number1
DOIs
Publication statusPublished - 2011 Jan 1
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Radiotherapy
Survival Rate
Cancer Care Facilities
Korea
Disease-Free Survival
Prostate
Adenocarcinoma
Retrospective Studies
Safety
Therapeutics

Keywords

  • CyberKnife
  • Localized prostate cancer
  • Stereotactic body radiation therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Kang, J. K., Cho, C. K., Choi, C. W., Yoo, S. Y., Kim, M. S., Yang, K. M., ... Jo, M. K. (2011). Image-guided stereotactic body radiation therapy for localized prostate cancer. Tumori, 97(1), 43-48. https://doi.org/10.1700/611.7137

Image-guided stereotactic body radiation therapy for localized prostate cancer. / Kang, Jin Kyu; Cho, Chul Koo; Choi, Chul Won; Yoo, Seong Yul; Kim, Mi Sook; Yang, Kwang Mo; Yoo, Hyung Jun; Kim, Jin Ho; Seo, Young Seok; Lee, Dong Han; Jo, Moon Ki.

In: Tumori, Vol. 97, No. 1, 01.01.2011, p. 43-48.

Research output: Contribution to journalArticle

Kang, JK, Cho, CK, Choi, CW, Yoo, SY, Kim, MS, Yang, KM, Yoo, HJ, Kim, JH, Seo, YS, Lee, DH & Jo, MK 2011, 'Image-guided stereotactic body radiation therapy for localized prostate cancer', Tumori, vol. 97, no. 1, pp. 43-48. https://doi.org/10.1700/611.7137
Kang, Jin Kyu ; Cho, Chul Koo ; Choi, Chul Won ; Yoo, Seong Yul ; Kim, Mi Sook ; Yang, Kwang Mo ; Yoo, Hyung Jun ; Kim, Jin Ho ; Seo, Young Seok ; Lee, Dong Han ; Jo, Moon Ki. / Image-guided stereotactic body radiation therapy for localized prostate cancer. In: Tumori. 2011 ; Vol. 97, No. 1. pp. 43-48.
@article{350147caff67408cb0b84c24ceef2b93,
title = "Image-guided stereotactic body radiation therapy for localized prostate cancer",
abstract = "Purpose.We report the results of a retrospective study of stereotactic body radiation therapy (SBRT) using CyberKnife for localized prostate cancer. The study focused on the safety and feasibility of this treatment modality. Materials and methods. Between October 2002 and December 2007, 44 patients suffering from localized adenocarcinoma of the prostate were treated with SBRT using CyberKnife at the Korea Cancer Center Hospital. The patients were divided into 3 groups: a low-risk group (5 patients), an intermediate-risk group (10 patients), and a high-risk group (29 patients). Five patients received 32 Gy in 4 fractions, 28 patients received 34 Gy in 4 fractions, and 11 patients received 36 Gy in 4 fractions. Results. The median age of the patients was 69 years (range, 53-79 years) and the median duration of follow-up 40 months (range, 12-78 months). There were 6 acute and 3 late grade 2 urinary toxicities, and 4 acute and 5 late grade 2 rectal toxicities, but there were no grade 3 or higher treatment-related toxicities. The 5-year cause-specific survival rate and progression-free survival rate were both 100{\%}. At last follow-up, the biochemical failure-free rate of the low-risk, intermediate-risk and high-risk patients was 100{\%}, 100{\%} and 90.8{\%}, respectively. Conclusion. SBRT using CyberKnife for localized prostate cancer is safe and well tolerated. We obtained promising results with 34 Gy in a 4-fraction regimen especially for the high-risk patients. Free full text available at www.tumorionline.it.",
keywords = "CyberKnife, Localized prostate cancer, Stereotactic body radiation therapy",
author = "Kang, {Jin Kyu} and Cho, {Chul Koo} and Choi, {Chul Won} and Yoo, {Seong Yul} and Kim, {Mi Sook} and Yang, {Kwang Mo} and Yoo, {Hyung Jun} and Kim, {Jin Ho} and Seo, {Young Seok} and Lee, {Dong Han} and Jo, {Moon Ki}",
year = "2011",
month = "1",
day = "1",
doi = "10.1700/611.7137",
language = "English",
volume = "97",
pages = "43--48",
journal = "Tumori",
issn = "0300-8916",
publisher = "Wichtig Publishing",
number = "1",

}

TY - JOUR

T1 - Image-guided stereotactic body radiation therapy for localized prostate cancer

AU - Kang, Jin Kyu

AU - Cho, Chul Koo

AU - Choi, Chul Won

AU - Yoo, Seong Yul

AU - Kim, Mi Sook

AU - Yang, Kwang Mo

AU - Yoo, Hyung Jun

AU - Kim, Jin Ho

AU - Seo, Young Seok

AU - Lee, Dong Han

AU - Jo, Moon Ki

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Purpose.We report the results of a retrospective study of stereotactic body radiation therapy (SBRT) using CyberKnife for localized prostate cancer. The study focused on the safety and feasibility of this treatment modality. Materials and methods. Between October 2002 and December 2007, 44 patients suffering from localized adenocarcinoma of the prostate were treated with SBRT using CyberKnife at the Korea Cancer Center Hospital. The patients were divided into 3 groups: a low-risk group (5 patients), an intermediate-risk group (10 patients), and a high-risk group (29 patients). Five patients received 32 Gy in 4 fractions, 28 patients received 34 Gy in 4 fractions, and 11 patients received 36 Gy in 4 fractions. Results. The median age of the patients was 69 years (range, 53-79 years) and the median duration of follow-up 40 months (range, 12-78 months). There were 6 acute and 3 late grade 2 urinary toxicities, and 4 acute and 5 late grade 2 rectal toxicities, but there were no grade 3 or higher treatment-related toxicities. The 5-year cause-specific survival rate and progression-free survival rate were both 100%. At last follow-up, the biochemical failure-free rate of the low-risk, intermediate-risk and high-risk patients was 100%, 100% and 90.8%, respectively. Conclusion. SBRT using CyberKnife for localized prostate cancer is safe and well tolerated. We obtained promising results with 34 Gy in a 4-fraction regimen especially for the high-risk patients. Free full text available at www.tumorionline.it.

AB - Purpose.We report the results of a retrospective study of stereotactic body radiation therapy (SBRT) using CyberKnife for localized prostate cancer. The study focused on the safety and feasibility of this treatment modality. Materials and methods. Between October 2002 and December 2007, 44 patients suffering from localized adenocarcinoma of the prostate were treated with SBRT using CyberKnife at the Korea Cancer Center Hospital. The patients were divided into 3 groups: a low-risk group (5 patients), an intermediate-risk group (10 patients), and a high-risk group (29 patients). Five patients received 32 Gy in 4 fractions, 28 patients received 34 Gy in 4 fractions, and 11 patients received 36 Gy in 4 fractions. Results. The median age of the patients was 69 years (range, 53-79 years) and the median duration of follow-up 40 months (range, 12-78 months). There were 6 acute and 3 late grade 2 urinary toxicities, and 4 acute and 5 late grade 2 rectal toxicities, but there were no grade 3 or higher treatment-related toxicities. The 5-year cause-specific survival rate and progression-free survival rate were both 100%. At last follow-up, the biochemical failure-free rate of the low-risk, intermediate-risk and high-risk patients was 100%, 100% and 90.8%, respectively. Conclusion. SBRT using CyberKnife for localized prostate cancer is safe and well tolerated. We obtained promising results with 34 Gy in a 4-fraction regimen especially for the high-risk patients. Free full text available at www.tumorionline.it.

KW - CyberKnife

KW - Localized prostate cancer

KW - Stereotactic body radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=79953860825&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953860825&partnerID=8YFLogxK

U2 - 10.1700/611.7137

DO - 10.1700/611.7137

M3 - Article

C2 - 21528663

AN - SCOPUS:79953860825

VL - 97

SP - 43

EP - 48

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 1

ER -